前列腺癌超声微泡介导药物及基因治疗研究进展

前列腺癌超声微泡介导药物及基因治疗研究进展

刘芸¹,赵云¹,刘朝奇²,胡兵¹

1. 湖北省宜昌市三峡大学
2. 湖北省宜昌市三峡大学医学院

收稿日期:2013-07-15 修回日期:2013-11-02 出版日期:2014-05-15 发布日期:2014-05-15
通讯作者: 刘芸

Advances in Ultrasound Microbubble-Mediated Gene and Drug Therapy for Prostate Cancer

Received:2013-07-15 Revised:2013-11-02 Published:2014-05-15 Online:2014-05-15
Contact: yun LIU

刘芸1 ,赵云1 ,刘朝奇2 ,胡兵1 . 前列腺癌超声微泡介导药物及基因治疗研究进展[J]. .

摘要/Abstract

摘要： 【摘要】前列腺癌是老年男性常见的恶性肿瘤。目前，对于前列腺癌晚期患者而言，基因治疗是其最有效的治疗方式。然而，病毒或非病毒载体多存在安全性低、靶向性差、免疫原性高等缺点。超声微泡造影剂作为一种新型基因载体，具有靶向性高、转染率高、安全性高等特点，为晚期前列腺癌患者的基因治疗带来了新的希望。现就该技术在前列腺癌治疗方面的研究进展做一综述。

Abstract: [Abstract] Prostate cancer is the most prevalent malignancies in elderly men. At present, gene therapy is the most po?
tential treatment for late- stage prostate cancer. However, virus vector or nonvirus vector are less safety, weaker targeting function and higher immunogenic. Ultrasound microcapsular contrast agent as a drug transporter is a new type of disease targeted treatment strategies. It has provided a high-targeted, an effective and a safety gene therapy for prostate cancer, and brings a new hope for late-stage prostate cancer patients. This article aims to summarize the recent progress in using the microbubble technology in prostate cancer.